Cancer Research

Cancer genomes are notoriously complex—with abnormal chromosome structures, somatic variations, and intricate rearrangements caused by events such as chromothripsis. These obstacles can make the critical, accurate detection of SVs with traditional genomic tools a daunting task. They also create significant obstacles in mapping tumor progression, which is critical for understanding cancer development and treatment resistance.

Why Current Technologies Struggle: 

• Limited detection capability: SV size and type complexities can limit detection ability 
• High-resolution detection inaccessibility: Detection beyond 300 bp often remains beyond reach
• Critical gaps: Multi-platform approaches still leave critical gaps

The OhmX Platform closes these gaps. Using advanced electronic genome mapping (EGM) technology, the platform empowers researchers with critical SV identification tailored for cancer’s unique genomic profiles—from deletions and duplications to complex aberrations. 

1. Validated Accuracy

In the technical note, [Verification of Structural Variants in Tumor Cells using EGM](LINK TO TECH NOTE), we evaluate the ability of EGM to detect and confirm a set of high-confidence SVs (hcSVs) defined as being detected by 2 or more techniques in a previous study.¹

The OhmX Platform demonstrated a robust verification rate of 70% for hcSVs, similar to the validation capabilities of other technologies reported by the original study.

2. High Concordance with Long-Read Data

EGM demonstrated high concordance with long-read sequencing technologies, ensuring reliable and reproducible results.

For more information, see Long-Read Sequencing Validation.

3. Low-Cost Acquisition Options

Get powerful results without breaking the bank. Our approach delivers exceptional performance at a fraction of the cost compared to alternative approaches. 

With zero upfront costs and an 8 genome per month commitment, our Reagent Rental Program makes EGM accessible to all researchers regardless of budget.

The OhmX Platform provides the accuracy and clarity you need to tackle the complexities of cancer genomics. Whether you're uncovering unknown SVs or mapping tumor progression, our cutting-edge technology empowers you to obtain actionable insights with confidence.